257 related articles for article (PubMed ID: 32207669)
1. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.
Hall ET; Fernandez-Lopez E; Silk AW; Dummer R; Bhatia S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32207669
[TBL] [Abstract][Full Text] [Related]
2. Where do we stand with immunotherapy for nonmelanoma skin cancers in the curative setting?
Alberti A; Gurizzan C; Baggi A; Bossi P
Curr Opin Otolaryngol Head Neck Surg; 2024 Apr; 32(2):89-95. PubMed ID: 37997885
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ; Djavid AR; Grimes JM; Khaleel AE; Soliman YS; Maisel-Campbell A; Garcia-Saleem TJ; Geskin LJ; Carvajal RD
Front Oncol; 2021; 11():734354. PubMed ID: 34988009
[TBL] [Abstract][Full Text] [Related]
5. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
[TBL] [Abstract][Full Text] [Related]
6. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapies for Advanced Basal Cell and Cutaneous Squamous Cell Carcinomas: Novel Targeted Therapies and Immunotherapies.
Krišto M; Šitum M; Čeović R
Acta Dermatovenerol Croat; 2020 Aug; 28(2):80-92. PubMed ID: 32876033
[TBL] [Abstract][Full Text] [Related]
8. Non-Melanoma Skin Cancer in People Living With HIV: From Epidemiology to Clinical Management.
Venanzi Rullo E; Maimone MG; Fiorica F; Ceccarelli M; Guarneri C; Berretta M; Nunnari G
Front Oncol; 2021; 11():689789. PubMed ID: 34422644
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
10. Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer.
Tanese K; Nakamura Y; Hirai I; Funakoshi T
Front Med (Lausanne); 2019; 6():160. PubMed ID: 31355203
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for nonmelanoma skin cancer: does it have a future?
Urosevic M; Dummer R
Cancer; 2002 Jan; 94(2):477-85. PubMed ID: 11900233
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
13. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer.
Lin A; Schmalbach CE
Curr Oncol Rep; 2023 Jul; 25(7):735-742. PubMed ID: 37010785
[TBL] [Abstract][Full Text] [Related]
14. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
15. Association between Blood Group and Nonmelanoma Skin Cancers (Basal Cell Carcinoma and Squamous Cell Carcinoma).
Celić D; Lipozenčić J; Kolarić B; Ferenčak G; Rajković JK; Borlinić T
Int J Environ Res Public Health; 2019 Jun; 16(13):. PubMed ID: 31252537
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Merkel cell carcinoma.
Angeles CV; Sabel MS
J Surg Oncol; 2021 Mar; 123(3):775-781. PubMed ID: 33595894
[TBL] [Abstract][Full Text] [Related]
18. Skin cancers in Croatia, 2003-2005: epidemiological study.
Lipozencić J; Celić D; Strnad M; Toncić RJ; Pasić A; Rados J; Znaor A
Coll Antropol; 2010 Sep; 34(3):865-9. PubMed ID: 20977074
[TBL] [Abstract][Full Text] [Related]
19. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
